For years to come, people will talk about how they survived the grueling periods of isolation and boredom brought to us by the COVID-19 pandemic. For many Americans and Canadians, the answer to that question is microdosing psychedelics.
A recent report from Gwella Mushrooms—a Canadian company that specializes in alternative mushroom-based wellness and increased psychedelic awareness—found that an overwhelming 91 percent of the 1000 respondents across North America began or continued microdosing over the past two years due to COVID-19. Nearly 50 percent of the 2022 Gwella Microdosing Survey respondents said that they began microdosing because of the pandemic, and another 41 percent said they microdosed more often due to the COVID-19 pandemic.
Read Report Here
Table of contents